Full Text View
Tabular View
Study Results
Related Studies
Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer
This study has been completed.
Study NCT00193128   Information provided by Sarah Cannon Research Institute

First Received on September 12, 2005.   Last Updated on March 26, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Esophagus Cancer
Additional conditions recognized in this trial
Esophageal Neoplasms
More general conditions related to this trial
Digestive System Diseases
Digestive System Neoplasms
Esophageal Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Head and Neck Neoplasms
Neoplasms
Neoplasms by Site
Interventions listed in this trial
Oxaliplatin
Docetaxel
Capecitabine
Radiation therapy
Additional drug interventions recognized in this trial
Fluorouracil
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Sarah Cannon Research Institute
Sanofi-Synthelabo
Aventis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services